ImmunityBio (IBRX) Other Non-Current Assets (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Other Non-Current Assets data on file, last reported at $15.7 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $15.7 million, up 4065.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.7 million (up 4065.61% YoY), and the FY2025 annual result was $378000.0, down 91.5% from the prior year.
• Other Non-Current Assets improved to $15.7 million in Q1 2026 per IBRX's latest filing, from $378000.0 in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $15.7 million in Q1 2026 and troughed at $378000.0 in Q1 2025.
• A 5-year average of $4.2 million and a median of $3.6 million in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets slumped 91.5% in 2025, then soared 4065.61% in 2026.
• A 5-year view of Other Non-Current Assets shows it stood at $4.9 million in 2022, then tumbled by 40.74% to $2.9 million in 2023, then surged by 54.48% to $4.4 million in 2024, then tumbled by 91.5% to $378000.0 in 2025, then soared by 4065.61% to $15.7 million in 2026.
• Business Quant data shows IBRX's Other Non-Current Assets at $15.7 million in Q1 2026, $378000.0 in Q4 2025, and $700000.0 in Q3 2025.